[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progression-free-survival\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progression-free-survival":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,81,105,136,162,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634686","sintilimab-chidamide-and-azacitidine-for-untreated-stage-i-ii-extranodal-nkt-cell-lymphoma-100634686",false,"NCT07542912","Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK\u002FT-Cell Lymphoma","A Single-Arm, Multicenter, Phase II Study of Sintilimab Combined With Chidamide and Azacitidine in Patients With Treatment-Naïve Stage I-II Extranodal Natural Killer\u002FT-Cell Lymphoma (SCENT-3)","SCENT-3","Inclusion Criteria:\n\n1. Willingness to participate in the clinical study.\n2. Age ≥ 18 years at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed ENKTL confirmed by histopathology at the study center.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n5. At least one evaluable or measurable lesion\n6. Ann Arbor stage I-II disease.\n7. PINK-E score ≥ 1.\n8. Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or abnormalities in cardiac, pulmonary, hepatic, renal, or thyroid function, and no immunodeficiency.\n\nExclusion Criteria:\n\n1. Aggressive natural killer cell leukemia.\n2. Presence of hemophagocytic syndrome.\n3. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.\n4. Patients with a known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome (AIDS).\n5. Patients with active chronic hepatitis B or active hepatitis C.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK\u002FT-cell Lymphoma (ENKTL). The study consists of a Screening Phase, a Safety Lead-in Phase, and a Treatment Phase. During the Safety Lead-in Phase, 6 patients will be enrolled to receive a fixed dose of Sintilimab and Chidamide combined with Azacitidine to verify the dose (testing 100mg\u002Fd on days 1-3 versus days 1-5). Following the lead-in, all subjects will undergo a 2-cycle Immunotherapy Induction Phase with the SCA regimen (Sintilimab, Chidamide, and Azacitidine). Subsequently, treatment will be stratified based on response: patients achieving Complete Response (CR) or Partial Response (PR) will receive 4 additional cycles of SCA consolidation, while those with Stable Disease (SD) or Progressive Disease (PD) will switch to 4 cycles of P-GemOx chemotherapy. Upon completion of systemic therapy, all patients will undergo consolidative involved-field radiotherapy (≥50Gy).",[27,28,29,30,31],"Complete Remission Rate， CRR","Progression Free Survival","Overall Survival","Adverse Event","Duration of Response",[33,34,35,36,37],"Extranodal NK\u002FT-cell Lymphoma","First-line Therapy","Sintilimab","Chidamide","Azacitidine","NOT_YET_RECRUITING","2026-04-17",{"date":41,"type":42},"2026-04-21","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2029-06-01",{"name":48,"class":49},"Sun Yat-sen University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100441118","long-term-follow-up-of-subjects-treated-with-car-t-cells-100441118","NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements",{"count":58,"type":21},45,"OBSERVATIONAL","This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[62,63,64,65,66,67,29],"Long Term Adverse Effects","CAR-T","Duty to Follow Up","Adult","Progression-Free Survival","Disease-Free Survival",[69,70],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies","RECRUITING","2026-03-13",{"date":74,"type":42},"2026-03-16",{"date":76,"type":42},"2023-08-07",{"date":78,"type":21},"2039-08-01",{"name":80,"class":49},"Marcela V. Maus, M.D.,Ph.D.",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":50},"100579576","phase-2-metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy-100579576","NCT06826092","Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy","Metformin as an Adjunctive Therapy for the Treatment of Metastatic Colorectal Cancer Patients Undergoing FOLFIRI Plus Target Therapy","Inclusion Criteria:\n\n1. Aged between 20 and 90 years old\n2. Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy\n3. Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)\n4. Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)\n5. Those who are not allergic to the relevant drugs required for the test\n6. Those who can follow the doctor's order to take the medicine\n7. Subjects must be willing to sign the consent form\n8. Blood sugar level above 80 mg\u002FdL\n\nExclusion Criteria:\n\nSubjects who meet any of the following exclusion conditions are not allowed to join the trial\n\n1. Patients other than the above-mentioned main inclusion criteria.\n2. Non-native speakers\n3. Known allergy to metformin or any of its components.\n4. Severe instability in diabetes (ketoacidosis).\n5. Blood sugar level lower than 80 mg\u002FdL\n6. Heart failure, respiratory insufficiency.\n7. inadequate hematopoietic function defined as below:\n\n   * hemoglobin \\\u003C 9 g\u002FdL;\n   * absolute neutrophil count (ANC) \\\u003C 1,500\u002Fmm3;\n   * platelet count \\\u003C 100,000\u002Fmm3;\n8. inadequate organ functions defined as below:\n\n   * total bilirubin \\> 2 times upper limit of normal (ULN);\n   * hepatic transaminases (ALT and AST) \\> 2.5 x ULN;\n   * creatinine \\> 1.5 x ULN;","20 Years","90 Years",{"count":91,"type":21},110,[93],"PHASE2","To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin",[66],"2025-02-10",{"date":98,"type":42},"2025-02-13",{"date":100,"type":42},"2022-10-31",{"date":102,"type":21},"2025-12-31",{"name":104,"class":49},"Kaohsiung Medical University Chung-Ho Memorial Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":50},"100542116","phase-3-survival-with-olanzapine-in-patients-with-locally-advanced-or-metastatic-upper-gastrointestinal-and-lung-cancer-100542116","NCT06338683","Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","Survival With the Addition of Olanzapine to Anticancer Therapy in Patients With Locally Advanced, Unresectable or Metastatic Gastric, Esophageal, Hepatopancreaticobiliary and Lung Cancer: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Eastern Cooperative Oncology Group performance status of 0-3;\n3. Stage III or IV inoperable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer and lung cancer confirmed by histology or cytology;\n4. Subjected to palliative systemic chemotherapy, regardless of first-line or second-line treatment;\n5. Expected survival ≥ 3 months;\n6. The patient is eligible for oral administration without dietary restrictions;\n7. Exhibits a favorable adherence to treatment and follow-up, demonstrates compliance with the research protocol, and willingly signs the informed consent form.\n\nExclusion Criteria:\n\n1. Weight loss and gain may be attributed to alternative factors, such as edema or ascites;\n2. Suffers from mental disorders or is under the medication of any antipsychotic or antidepressant drugs;\n3. History of central nervous system disorders (such as brain metastasis, epilepsy;\n4. Patients undergoing sustained administration of sedative medications or long-term hormonal therapy, individuals with chronic alcoholism, or those with substance dependence on medications;\n5. Prohibition of Olanzapine Intake for Contraindicated Individuals;\n6. History of clozapine-induced agranulocytosis because patients will be at increased risk for neutropenia with Olanzapine;\n7. Uncontrolled diabetes mellitus and Uncontrolled seizure disorder;\n8. Pregnant and Nursing women;\n9. Exclusion criteria include active participation in another interventional clinical trial, ongoing involvement in an observational (noninterventional) clinical trial, or being in the survival follow-up phase of an interventional clinical trial;\n10. Researchers posit that any condition deemed potentially harmful to the subjects or that might prevent subjects from meeting or adhering to the research requirements shall not be permissible for inclusion in this study.",true,"80 Years",{"count":115,"type":21},230,[117],"PHASE3","This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.",[120,121,28],"Advanced Cancer","Olanzapine",[123,124,125,126],"advanced cancer","olanzapine","chemotherapy","progression free survival","2024-03-28",{"date":129,"type":42},"2024-03-29",{"date":131,"type":42},"2024-03-20",{"date":133,"type":21},"2028-03-20",{"name":135,"class":49},"Qinghai Red Cross Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":50},"100532645","a-novel-target-delineation-scheme-in-high-grade-glioma-patients-a-randomized-single-blind-clinical-trial-100532645","NCT06215495","A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial","A Novel Target Delineation Scheme Based on RTOG(Radiation Therapy Oncology Group) and EORTC(European Organisation for Research and Treatment of Cancer) Guidelines Impact on Survival Time and Radiotherapy Complications in High-grade Glioma Patients: a Single-center Randomized Single-blind Clinical Trial","Inclusion Criteria:\n\n1. High-grade glioma (2021 WHO grade III or IV)\n2. Age between 18-65 years old, Karnofsky performance status (KPS) score ≥ 70\n3. result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential\n4. The patient voluntarily joined this study and signed an informed consent form\n5. Willing to return for follow-up\n6. Willing to provide tissue and blood samples for this research\n7. Surgical treatment was completed without any postoperative complications (such as consciousness disorders, hematomas, lung infection and cardiac insufficiency)\n8. Radiotherapy within 4-6 weeks after surgery\n9. No contraindications for taking temozolomide\n\nExclusion Criteria:\n\n1. Low-grade glioma(2021 WHO grade I or II)\n2. had or having other type of malignant cancers\n3. not having been performed gross total resection of tumor\n4. Severe active comorbidities, systemic diseases or other serious comorbidities that would render the patient unsuitable for participation in this study or seriously interfere with the appropriate evaluation of the safety and toxicity of the prescribed regimen in the judgment of the investigator, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, or mental illness；\n5. Baseline MRI indicates a previous or recent risk of cerebral hemorrhage or hernia;\n6. Pregnancy or lactation, or pregnancy or childbirth during the expected trial period(from pre-screening or screening visits until 120 days after the last trial treatment)\n7. Unable to perform brain magnetic resonance imaging;\n8. Allergic to CT contrast agent, unable to perform enhanced CT examination;\n9. Remote transfer;\n10. Medical contraindications for receiving radiation therapy, such as active systemic lupus or scleroderma","65 Years",{"count":145,"type":21},88,[24],"The main question it aims to answer are:\n\n1. whether the new target delineation scheme can improve Progression-free Survival\n2. whether it can reduce the incidence of radiation complications in high-grade glioma patients.\n\nParticipants in trial group will be performed radiotherapy of new target delineation method after the completion of the operation within 4-6 weeks., while participants in the control group be performed radiotherapy of EORTC(European organisation for research and treatment of cancer) target delineation method.Temozolomide 75 mg \u002F ( m² · d ) will be given to both groups of patients during radiotherapy. After radiotherapy, its dose changes to 150 \\~ 200 mg \u002F ( m² · d ) for 5 days and stopped for 23 days as a cycle. There are 6 cycles in total.",[149,150,151,152,29],"Radiation Toxicity","MRI Simulated Positioning","High Grade Glioma","Progression-free Survival","2024-03-12",{"date":155,"type":42},"2024-03-15",{"date":157,"type":42},"2024-02-18",{"date":159,"type":21},"2027-06-01",{"name":161,"class":49},"Zhujiang Hospital",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":50},"100434172","phase-2-prospective-multicenter-clinical-study-of-neoadjuvant-imatinib-mesylate-for-gastrointestinal-stromal-tumors-100434172","NCT04933669","Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","ZJGIST-01","Inclusion Criteria:\n\n* Preoperative histologically confirmed primary gastrointestinal stromal tumor\n* Tumor must stain positive for c-Kit (CD117) and\u002For discovered on gist-1 (DOG-1) by immunohistochemistry\n* Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18\n* High risk GIST (as modified National Institutes of Health (NIH) 2008): stomach (maximum tumor diameter\\> 10.0cm), nonstomach (maximum tumor diameter\\> 5.0cm)\n* Gender is not limited. Age: ≥ 18 years and ≤ 80 years old\n* Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1\n* Patient had informed consent and signed a written consent form\n\nExclusion Criteria:\n\n* Asp842Val (D842V) mutation in Exon 18 of PDGFRA gene, or wild type (c-kit exon 9,11,13,17, and PDGFRA Exon 12,18), or c-kit exon 9 mutation\n* Treated with tyrosine kinase inhibitors including Imatinib\n* Aspartate aminotransferase (AST) and\u002For Alanine aminotransferase (ALT)\\>2.5×ULN(upper limit of normal)，or Total bilirubin (TBIL)\\>1.5×ULN，or Creatinine (Cr)\\>1.0×ULN\n* Absolute neutrophil count (ANC) \\\u003C 1.5 × 10 \\^ 9 \u002F L；or Platelet count (PLT) \\\u003C 75 × 10 \\^ 9 \u002F L；or Hemoglobin (Hb) ≥ 90 g \u002F L\n* Previous or concurrent other active malignant tumors (except for basal cell carcinoma of the skin, or cervical cancer in situ that has undergone curative therapy)\n* Distant metastases are present\n* Any of the following conditions during the 12 months prior to entry: myocardial infarction, severe \u002F unstable angina, coronary artery \u002F peripheral artery bypass surgery, symptomatic congestive heart failure, or cerebrovascular accidents\n* positive Human Immunodeficiency Virus (HIV) antibody\n* Currently participating in other clinical trials\n* Pregnant or lactating women or have fertility without taking contraception\n* Suffering from other serious acute and chronic physical or mental problems, or abnormal laboratory tests, will increase the risk of participation or drug use, or interfere with the judgment of the findings, judged by the researchers as participate in the study",{"count":170,"type":21},122,[93],"The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. A few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.",[152,174,175],"Gastrointestinal Stromal Tumor","Neoadjuvant",[177,178,179],"Progression-free survival","Gastrointestinal Stromal Tumors","neoadjuvant","2021-10-09",{"date":182,"type":42},"2021-10-12",{"date":184,"type":42},"2021-09-07",{"date":186,"type":21},"2029-12-31",{"name":188,"class":49},"First Affiliated Hospital of Zhejiang University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":205,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100372312","efficacy-of-postoperative-radiotherapy-for-atypical-meningioma-without-venous-sinus-invasion-after-gross-total-resection-100372312","NCT04127760","Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection","A Multicenter Randomized Controlled Trial of the Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection","Inclusion Criteria:\n\n* Patients who underwent gross total resection at each center and were diagnosed as atypical meningioma (WHO class II) according to the WHO 2016 diagnostic criteria.\n* Gross total resection was defined as modified Simpson 1-3 and confirmed by postoperative magnetic resonance imaging.\n\nExclusion Criteria:\n\n* age less than 18 years old or older than 70 years\n* meningioma recurrence\n* patients had previous radiotherapy\n* multiple meningioma\n* optic nerve sheath meningioma or other extracranial meningioma\n* tumor involving venous sinus\n* ECOG score ≥ 2 points\n* preoperative ASA grade ≥ 3\n* previous or current malignant tumors\n* pregnant or lactating women\n* Patients with Gd-DTPA allergies, spatial claustrophobia or pacemaker implantation that can not be conducted constract-enhanced head magnetic resonance examination\n* patients who were unable to obtain informed consent or refused to participate in the study.","70 Years",{"count":198,"type":21},140,[24],"Postoperative adjuvant radiotherapy is a key component of comprehensive treatment of meningioma. However, for atypical meningioma after total resection, there is still a huge controversy in patients who need adjuvant radiotherapy after surgery.\n\nMany scholars have focused on this problem and carried out some small-scale retrospective studies, but they have contradictory results. Some of the studies found that postoperative adjuvant radiotherapy could not improve the prognosis of patients, but was questioned because the sample size was too small, resulting in insignificant results, while other studies found that postoperative adjuvant radiotherapy can improve progression free survival. A study based on the National Cancer Database found that postoperative adjuvant radiotherapy and gross tumor resection are associated with a good prognosis. A recent meta-analysis enrolled a total of 757 patients and found that postoperative adjuvant radiotherapy reduced the risk of tumor recurrence but did not improve survival time. Our team reviewed the meningioma data in the SEER database and conducted a study previously. The study found that postoperative adjuvant radiotherapy did not improve the overall survival of these patients. The relevant research results were recently published in Frontiers in oncology. We further reviewed and summarized the single-center data of our hospital and found that postoperative adjuvant radiotherapy could not improve the progression free survival and overall survival of patients. Besides, we also performed a meta-analysis and found that postoperative adjuvant radiotherapy had a trend to improve progression-free survival, but there was no statistical difference.\n\nBecause there are many deficiencies in previous researches, and the research results are also contradictory, it is still unclear whether patients with atypical meningioma who have undergone gross total resection can benefit from postoperative adjuvant radiotherapy. Further high quality clinical trials is still needed to be conducted in order to guide the postoperative care of patients. Therefore, we intend to conduct this multicenter randomized controlled trial to determine the value of postoperative adjuvant radiotherapy in patients with atypical meningioma who underwent gross total resection.",[202,203,66,204],"Meningioma Atypical","Radiotherapy","Adverse Effect of Radiation Therapy",[202,206],"radiotherapy","2019-10-15",{"date":209,"type":42},"2019-10-16",{"date":211,"type":21},"2020-01-01",{"date":213,"type":21},"2033-01-01",{"name":215,"class":49},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]